普伐他汀与辛伐他汀的调脂疗效与安全性比较  

Pravastatin vs. Simvastatin in Lipid-regulating Efficacy and Safety

作　　者：郑东诞[1] 高修仁[1] 杨伟权[1] 王强[1] 李树斌[1] 梅卫义[1] 

机构地区：[1]中山大学附属第一医院,广州市510080

出　　处：《中国药房》2009年第5期367-369,共3页China Pharmacy

摘　　要：目的:比较普伐他汀与辛伐他汀降低低密度脂蛋白胆固醇(LDL-C)和升高高密度脂蛋白胆固醇(HDL-C)的临床疗效,并观察其安全性。方法:66例高胆固醇血症患者随机分为2组,各33例,每晚分别服用普伐他汀40mg或辛伐他汀40mg,连续6周。所有患者均在入选时和服药后6周抽血检查血脂,主要指标是LDL-C相对于基线值的变化,次要指标是HDL-C。安全性的评价依据实验室检查结果和临床记录的副反应。结果:普伐他汀与辛伐他汀均能明显降低LDL-C,治疗前、后比较差异有统计学意义(P<0.05);均可轻度升高HDL-C,治疗前、后比较差异无统计学意义(P>0.05)。2药的副作用均较少。结论:普伐他汀与辛伐他汀的调脂作用相当,均具有很好的耐受性。OBJECTIVE： To evaluate the efficacy and safety of Pravastatin versus Simvastatin in downregulating low density lipoprotein cholesterol （LDL-C） and upregulating high density lipoprotein cholesterol （HDL-C） . METHODS： A total of 66 patients with hypercholesterolemia were enrolled： 33 were randomly assigned to receive Pravastatin （40 mg） for 6 weeks, and another 33 to receive Simvastatin （40 rag） for 6 weeks. Serum lipid levels at baseline and 6 weeks after medication were measured. The primary effective indicator was LDL- C as compared with baseline value and the secondary effective indicator was HDL- C. Safety was evaluated based on laboratory data and clinical adverse reactions. RESULTS： Both Pravastatin and Simvastatin significantly decreased LDL - C level, showing significant differences as compared with before medication （P〈0.05）, and HDL- C was slightly increased by either Pravastatin or Simvastatin, but the difference was not significant （P 〉 0.05） . Less adverse drug reactions were noted in both groups. CONCLUSION： Pravastatin and Simvastatin were equivalent in lipid - regulatory effect and both were well - tolerated.

关 键 词：高脂血症 普伐他汀 辛伐他汀 

分 类 号：R969.4[医药卫生—药理学] R977.6[医药卫生—药学]